ijms-logo

Journal Browser

Journal Browser

New Trends in Research on Cerebral Ischemia

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1036

Special Issue Editor


E-Mail Website
Guest Editor
Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Tokyo 162-8543, Japan
Interests: white matter damage; dementia, motor impairment; functional recovery axonal regeneration; cell transplantation, exosome therapy

Special Issue Information

Dear Colleagues,

This Special Issue delves into the intricate relationship between white matter damage resulting from ischemia and the potential for axon regeneration via the application of innovative interventions such as cell transplantation and exosome therapy. Ischemia-induced white matter injury is a major contributor to neurological disorders, leading to significant cognitive and motor impairments.

Through a comprehensive analysis of current research, this Special Issue aims to thoroughly examine the underlying mechanisms of white matter damage in ischemia, with a particular emphasis on its detrimental effects on axonal structures and myelin integrity. The molecular and cellular alterations triggered by ischemic events are elucidated, shedding light on the factors influencing the regenerative potential of axons.

The primary focus of this Special Issue is the exploration of cutting-edge interventions that exhibit promise in promoting axon regeneration. Cell transplantation emerges as a leading strategy, harnessing the regenerative capacity of stem cells to replace damaged cells and facilitate neural repair. Additionally, this Special Issue aims to delve into the emerging field of exosome therapy, which utilizes extracellular vesicles in order to deliver the therapeutic cargo, stimulate growth, and modulate the regenerative response within the affected white matter.

By synthesizing insights from various studies and clinical trials, this Special Issue will not only advance our understanding of ischemia-induced white matter damage, but also offer a glimpse into the potential of groundbreaking interventions for axon regeneration. This research will pave the way for enhanced treatments and functional recovery in patients affected by white matter injuries.

Dr. Hideaki Imai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • white matter damage
  • ischemia
  • axon regeneration
  • intervention
  • cell transplantation
  • exosome therapy
  • stem cells
  • myelin integrity
  • neurological disorders
  • neural repair
  • cognitive impairments

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1572 KiB  
Article
Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke
by Pablo Hervella, Ana Sampedro-Viana, Sabela Fernández-Rodicio, Manuel Rodríguez-Yáñez, Iria López-Dequidt, José M. Pumar, Antonio J. Mosqueira, Marcos Bazarra-Barreiros, María Teresa Abengoza-Bello, Sara Ortega-Espina, Alberto Ouro, María Pérez-Mato, Francisco Campos, Tomás Sobrino, José Castillo, Maria Luz Alonso-Alonso and Ramón Iglesias-Rey
Int. J. Mol. Sci. 2024, 25(12), 6554; https://doi.org/10.3390/ijms25126554 - 14 Jun 2024
Viewed by 537
Abstract
Glutamate grabbers, such as glutamate oxaloacetate transaminase (GOT), have been proposed to prevent excitotoxicity secondary to high glutamate levels in stroke patients. However, the efficacy of blood glutamate grabbing by GOT could be dependent on the extent and severity of the disruption of [...] Read more.
Glutamate grabbers, such as glutamate oxaloacetate transaminase (GOT), have been proposed to prevent excitotoxicity secondary to high glutamate levels in stroke patients. However, the efficacy of blood glutamate grabbing by GOT could be dependent on the extent and severity of the disruption of the blood–brain barrier (BBB). Our purpose was to analyze the relationship between GOT and glutamate concentration with the patient’s functional status differentially according to BBB serum markers (soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and leukoaraiosis based on neuroimaging). This retrospective observational study includes 906 ischemic stroke patients. We studied the presence of leukoaraiosis and the serum levels of glutamate, GOT, and sTWEAK in blood samples. Functional outcome was assessed using the modified Rankin Scale (mRS) at 3 months. A significant negative correlation between GOT and glutamate levels at admission was shown in those patients with sTWEAK levels > 2900 pg/mL (Pearson’s correlation coefficient: −0.249; p < 0.0001). This correlation was also observed in patients with and without leukoaraiosis (Pearson’s correlation coefficients: −0.299; p < 0.001 vs. −0.116; p = 0.024). The logistic regression model confirmed the association of higher levels of GOT with lower odds of poor outcome at 3 months when sTWEAK levels were >2900 pg/mL (OR: 0.41; CI 95%: 0.28–0.68; p < 0.0001) or with leukoaraiosis (OR: 0.75; CI 95%: 0.69–0.82; p < 0.0001). GOT levels are associated with glutamate levels and functional outcomes at 3 months, but only in those patients with leukoaraiosis and elevated sTWEAK levels. Consequently, therapies targeting glutamate grabbing might be more effective in patients with BBB dysfunction. Full article
(This article belongs to the Special Issue New Trends in Research on Cerebral Ischemia)
Show Figures

Figure 1

Back to TopTop